期刊文献+

冠心病高脂血症患者应用阿托伐他汀长期调脂治疗的临床观察 被引量:5

Clinical observation on long-term lipid-regulating treatment with atorvastatin on coronary and hyperlipoproteinemia patients(CHP)
下载PDF
导出
摘要 目的研究冠心病、高脂血症患者长期应用阿托伐他汀调脂治疗的临床疗效、不良反应。方法110例冠心病、高脂血症患者在膳食控制和适当加强锻炼的基础上服用阿托伐他汀10~20mg,每晚1次;治疗6~12周后将达到治疗目标的患者改为服用阿托伐他汀10mg,隔日晚服1次,维持应用。每12周测总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、肝、肾功能、肌酸激酶(CK)。结果治疗6~12周后TC、LDL-C达调脂治疗目标值为89例(80.9%),TC、TG、LDL-C下降,HDL-C升高,与治疗前比较差异有统计学意义(P<0.01)。维持用药各时期各项指标比较差异无统计学意义(P>0.05);用药期间无明显肝肾功能损害及不良反应。结论阿托伐他汀调脂作用肯定,在10~20mg每晚1次的剂量下不良反应少,用药安全。在调脂达到目标值后,改为阿托伐他汀10mg,隔日晚服1次,长期维持,临床达标率亦满意。 Objective To study clinical efficacy and adverse reactions of long-term lipid-regulating treatment with atorvastatin on CHP.Methods 110 cases of CHP were administered atorvastain 10mg to 20mg each evening,along with dietary control and proper exercise.The cases whose treatment target values had been reached would alter doses to 10mg each other evening.TC、TG、HDL-C、CK and functions of liver and kidney were measured each 12 weeks.Results After treatment for 6 to 12 weeks,89 cases(80.9%)reached treatment values of TC,LDL-C among which the TC,TG and LDL-C decreased,but HDL-C increased.The above-mentioned indices were significantly different from those before treatment(P〈0.01).Continued the altered administration of atorvastatin,all indices at each stage had no significant difference(P〉0.05).There were no obvious injuries to the functions of liver and kidney,and adverse reactions.Conclusion Atorvastatin's action in lipid-regulating was definite and with dose of 10mg to 20mg every other evening,the administration was safe.When lipid-lowering reached the target values,the dose was altered to 10mg every other evening and maintained long and clinical target rate was satisfied.
出处 《临床合理用药杂志》 2010年第6期5-6,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 冠心病 高脂血症 阿托伐他汀 Coronary Hyperlipoproteinemia Atorvastatin
  • 相关文献

参考文献6

二级参考文献17

  • 1曾子健,阮孝萱.血浆载脂蛋白与老年糖尿病血管并发症[J].实用老年医学,1995,9(5):231-231. 被引量:1
  • 2李幼阳,安伶,孔可.肥胖型糖尿病并脂肪肝患者血清载脂蛋白B水平的临床观察[J].中国实用内科杂志,1995,15(6):346-347. 被引量:11
  • 3洪景范,张文华,隋洪.肾脏病患者血清载脂蛋白A1、B、高密度脂蛋白胆固醇水平及临床意义[J].中华医学检验杂志,1996,19(3):154-156. 被引量:14
  • 4National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ).Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ) fina1 report.Circulation,2002,106:3143-3421. 被引量:1
  • 5Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536high-risk individuals:a randomized placebo-controlled trial.Lancet,2002,360:7-22. 被引量:1
  • 6Cannon CP,Braunwald E,McCabe CH,et al.Pravastatin or Atorvastatin Evaluation and Infection Therapy.Thrombolysis in Myocardial Infarction22 Investigators,Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med,2004,350:1495-1504. 被引量:1
  • 7Lemos JA,Blazing MA,Wivott SD,et al.Early intensive vs a delayed conservative simavastatin strategy in patients with cute coronary syndrome.Phase Z of the A to Z trial.JAMA,2004,292:1307-1316. 被引量:1
  • 8Waters DD,Guyton JR,Herrington DM,et al.TNT Steering Committee Members and Investigators.Treating to New Targets (TNT) Study:does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cordiol,2004,93:154-158. 被引量:1
  • 9Alawi A.The Safety of Rosuvastatin as Used in Common Clinical Practice.A post marketing analysis.Circulation,2005,111:3051-3057. 被引量:1
  • 10Neaton JD,Blackburn H,Jacobs D,et al.Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial Arch Intern Med,1992,152:1490-1500. 被引量:1

共引文献3174

同被引文献27

引证文献5

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部